5 Most Promising Gene Editing Stocks According to Analysts

4. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 28

One-Year Average Price Target: $89.57

CRISPR Therapeutics AG (NASDAQ:CRSP) is perhaps the most popular gene editing company in the world. CRISPR Therapeutics AG (NASDAQ:CRSP) has a huge pipeline of treatments that use genome editing and sequencing to treat several diseases. As of March 6, CRISPR Therapeutics AG (NASDAQ:CRSP) is hovering around $49. CRISPR Therapeutics AG (NASDAQ:CRSP)’s average analyst price target stands at $89, which shows that the shares of CRISPR have a strong upside potential from the current levels.

CRISPR Therapeutics AG (NASDAQ:CRSP) shares jumped in February after the company posted Q4 results. CRISPR Therapeutics AG (NASDAQ:CRSP) discussed the regulatory prospects for its gene-edited therapy exa-cel co-developed with Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).